You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluoxetine
Accession NumberDB00472  (APRD00530)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.

Structure
Thumb
Synonyms
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Fluoxetin
Fluoxetina
Fluoxétine
Fluoxetinum
Prozac
External Identifiers
  • Lilly 103472
  • Lilly 110 140
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-fluoxetinecapsule10 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-fluoxetinecapsule20 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-fluoxetinecapsule10 mgoralAccord Healthcare Inc2012-10-10Not applicableCanada
Ach-fluoxetinecapsule20 mgoralAccord Healthcare Inc2012-05-01Not applicableCanada
Act Fluoxetinecapsule20 mgoralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Act Fluoxetinecapsule10 mgoralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Act Fluoxetinecapsule40 mgoralDr Reddys Laboratories IncNot applicableNot applicableCanada
Auro-fluoxetinecapsule20 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-fluoxetinecapsule10 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-fluoxetinecapsule20 mgoralAvanstra Inc2011-11-282014-08-21Canada
Bci Fluoxetinecapsule20 mgoralBaker Cummins IncNot applicableNot applicableCanada
Bio-fluoxetinecapsule20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-fluoxetinecapsule10 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-fluoxetinecapsule20 mgoralDominion Pharmacal1995-12-31Not applicableCanada
Dom-fluoxetine - Cap 10mgcapsule10 mgoralDominion Pharmacal1995-12-31Not applicableCanada
Fluoxetinecapsule20 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Fluoxetinecapsule20 mgoralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
Fluoxetinecapsule10 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Fluoxetinecapsule10 mgoralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
Fluoxetinecapsule20 mgoralSanis Health Inc2009-10-22Not applicableCanada
Fluoxetinesolution20 mgoralAa Pharma Inc1997-06-16Not applicableCanada
Fluoxetinecapsule10 mgoralSanis Health Inc2009-10-22Not applicableCanada
Fluoxetine Capsulescapsule20 mgoralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine Capsulescapsule10 mgoralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine HCltablet, film coated60 mg/1oralEdgemont Pharmaceuticals, Llc2011-11-14Not applicableUs
Fluoxetine-10 - Capcapsule10 mgoralPro Doc Limitee1997-04-302010-07-13Canada
Fluoxetine-20 - Capcapsule20 mgoralPro Doc Limitee1997-04-302010-07-13Canada
Fxt 10capsule10 mgoralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 20capsule20 mgoralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 40capsule40 mgoralSepracor Pharmaceuticals Inc2002-06-212011-08-03Canada
Ipg-fluoxetinecapsule20 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-fluoxetinecapsule10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-fluoxetinecapsule20 mgoralJamp Pharma Corporation2012-06-07Not applicableCanada
Jamp-fluoxetinecapsule10 mgoralJamp Pharma Corporation2013-04-30Not applicableCanada
Mar-fluoxetinecapsule20 mgoralMarcan Pharmaceuticals Inc2013-06-27Not applicableCanada
Mar-fluoxetinecapsule10 mgoralMarcan Pharmaceuticals Inc2013-05-07Not applicableCanada
Mint-fluoxetinecapsule10 mgoralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mint-fluoxetinecapsule20 mgoralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mylan-fluoxetinecapsule20 mgoralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Mylan-fluoxetinecapsule10 mgoralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Nu-fluoxetineliquid20 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-fluoxetinecapsule20 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Nu-fluoxetinecapsule10 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Penta-fluoxetine Capsulescapsule20 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-fluoxetine Capsulescapsule10 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PHL-fluoxetine - Cap 10mgcapsule10 mgoralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Cap 20mgcapsule20 mgoralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Solution 20mg/5mlsolution20 mgoralPharmel Inc1998-06-04Not applicableCanada
PMS-fluox Capsules 20mgcapsule20 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-fluoxetine - Cap 10mgcapsule10 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine - Cap 20mgcapsule20 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine Liquid - 20mg/5mlsolution20 mgoralPharmascience Inc1997-10-20Not applicableCanada
Priva-fluoxetinecapsule10 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-fluoxetinecapsule20 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-fluoxetinecapsule20 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Pro-fluoxetinecapsule10 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Prozaccapsule20 mg/1oralStat Rx USA1987-12-29Not applicableUs
Prozaccapsule40 mg/1oralDista Products Company1999-06-15Not applicableUs
Prozaccapsule20 mg/1oralDista Products Company1988-02-01Not applicableUs
Prozaccapsule10 mg/1oralDista Products Company1993-01-13Not applicableUs
Prozac Capsules 10mgcapsule10 mgoralEli Lilly Canada Inc1993-12-31Not applicableCanada
Prozac Capsules 20mgcapsule20 mgoralEli Lilly Canada Inc1989-12-31Not applicableCanada
Prozac Liq 20mg/5mlliquid20 mgoralEli Lilly Canada Inc1992-12-312007-08-29Canada
Prozac Weeklycapsule, delayed release90 mg/1oralEli Lilly and Company2001-03-16Not applicableUs
Q-fluoxetinecapsule10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-fluoxetinecapsule20 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-fluoxetinecapsule20 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ran-fluoxetinecapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ratio-fluoxetinecapsule20 mgoralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Ratio-fluoxetinecapsule10 mgoralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Riva-fluoxetinecapsule10 mgoralLaboratoire Riva Inc2000-05-232014-07-29Canada
Riva-fluoxetinecapsule20 mgoralLaboratoire Riva Inc2009-09-21Not applicableCanada
Riva-fluoxetinecapsule10 mgoralLaboratoire Riva Inc2010-10-22Not applicableCanada
Riva-fluoxetinecapsule20 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Sandoz Fluoxetinecapsule10 mgoralSandoz Canada Incorporated2001-02-22Not applicableCanada
Sandoz Fluoxetinecapsule20 mgoralSandoz Canada Incorporated2001-02-22Not applicableCanada
Sarafemtablet20 mg/1oralWarner Chilcott (US), LLC2008-06-24Not applicableUs
Sarafemtablet10 mg/1oralWarner Chilcott (US), LLC2008-06-24Not applicableUs
Stcc-fluoxetine - Cap 10mgcapsule10 mgoralStcc Inc.1995-12-312002-07-31Canada
Stcc-fluoxetine - Cap 20mgcapsule20 mgoralStcc Inc.1995-12-312002-07-31Canada
Teva-fluoxetinecapsule10 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Teva-fluoxetinecapsule20 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Van-fluoxetinecapsule20 mgoralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Van-fluoxetinecapsule10 mgoralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Zym-fluoxetinecapsule20 mgoralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Zym-fluoxetinecapsule10 mgoralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluoxetinecapsule20 mgoralApotex Inc1996-12-31Not applicableCanada
Apo-fluoxetinecapsule10 mgoralApotex Inc1996-12-31Not applicableCanada
Fluoxetinecapsule10 mg/1oralTYA Pharmaceuticals2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralLegacy Pharmaceutical Packaging2011-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule10 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinecapsule20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-20Not applicableUs
Fluoxetinetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
Fluoxetinecapsule40 mg/1oralTeva Pharmaceuticals USA Inc2012-08-29Not applicableUs
Fluoxetinecapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Fluoxetinecapsule10 mg/1oralRebel Distributors Corp2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-12-08Not applicableUs
Fluoxetinecapsule10 mg/1oralUnit Dose Services2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2005-07-20Not applicableUs
Fluoxetinecapsule10 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-06-032016-04-05Us
Fluoxetinesolution20 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-08-29Not applicableUs
Fluoxetinecapsule10 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule20 mg/1oralCardinal Health2011-07-11Not applicableUs
Fluoxetinecapsule20 mg/1oralReady Meds2008-01-31Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralProficient Rx LP2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralLegacy Pharmaceutical Packaging2011-01-25Not applicableUs
Fluoxetinecapsule10 mg/1oralCarlsbad Technology, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule20 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
Fluoxetinecapsule40 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2014-11-06Not applicableUs
Fluoxetinecapsule20 mg/1oralSTAT Rx USA LLC2012-03-20Not applicableUs
Fluoxetinecapsule40 mg/1oralUnit Dose Services2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralPliva Inc.2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Fluoxetinecapsule20 mg/1oralClinical Solutions Wholesale2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralCardinal Health2002-01-29Not applicableUs
Fluoxetinecapsule40 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
Fluoxetinecapsule40 mg/1oralProficient Rx LP2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralAmerican Health Packaging2013-02-04Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralProdigy Health Supplier2012-06-01Not applicableUs
Fluoxetinecapsule40 mg/1oralAidarex Pharmaceuticals LLC2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule40 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule20 mg/1oralUnit Dose Services2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralPliva Inc.2002-01-29Not applicableUs
Fluoxetineliquid20 mg/5mLoralSilarx Pharmaceuticals, Inc2009-08-27Not applicableUs
Fluoxetinecapsule10 mg/1oralREMEDYREPACK INC.2013-02-262016-04-05Us
Fluoxetinecapsule10 mg/1oralClinical Solutions Wholesale2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralCardinal Health2007-02-16Not applicableUs
Fluoxetinecapsule20 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
Fluoxetinecapsule10 mg/1oralProficient Rx LP2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralAmerican Health Packaging2013-12-10Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2012-03-20Not applicableUs
Fluoxetinecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralProdigy Health Supplier2012-06-01Not applicableUs
Fluoxetinecapsule10 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule20 mg/1oralMajor Pharmaceuticals2007-02-16Not applicableUs
Fluoxetinecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-05-20Not applicableUs
Fluoxetinesolution20 mg/5mLoralPharmaceutical Associates, Inc.2002-02-01Not applicableUs
Fluoxetinecapsule10 mg/1oralAidarex Pharmaceuticals LLC2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule20 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule40 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-02-252016-04-05Us
Fluoxetinecapsule40 mg/1oralClinical Solutions Wholesale2005-07-20Not applicableUs
Fluoxetinecapsule40 mg/1oralbryant ranch prepack2008-12-08Not applicableUs
Fluoxetinecapsule20 mg/1oralProficient Rx LP2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralBlue Point Laboratories2013-12-23Not applicableUs
Fluoxetinesolution20 mg/5mLoralAurobindo Pharma Limited2009-03-19Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2016-02-25Not applicableUs
Fluoxetinecapsule20 mg/1oralMc Kesson Contract Packaging2012-04-16Not applicableUs
Fluoxetinecapsule20 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Fluoxetinecapsule10 mg/1oralMajor Pharmaceuticals2007-02-16Not applicableUs
Fluoxetinecapsule20 mg/1oralAidarex Pharmaceuticals LLC2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralMedsource Pharmaceuticals2009-06-09Not applicableUs
Fluoxetinecapsule10 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule20 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-05-24Not applicableUs
Fluoxetinecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-10-15Not applicableUs
Fluoxetinecapsule40 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule20 mg/1oralbryant ranch prepack2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralMc Kesson Contract Packaging2011-10-17Not applicableUs
Fluoxetinecapsule10 mg/1oralSTAT Rx USA LLC2012-03-20Not applicableUs
Fluoxetinecapsule20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-29Not applicableUs
Fluoxetinesolution20 mg/5mLoralPharmaceutical Associates, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule10 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
Fluoxetinecapsule10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Fluoxetinecapsule20 mg/1oralPd Rx Pharmaceuticals, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule10 mg/1oralbryant ranch prepack2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Fluoxetinecapsule20 mg/1oralContract Pharmacy Services Pa2011-01-25Not applicableUs
Fluoxetinecapsule20 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralLife Line Home Care Services, Inc.2012-01-16Not applicableUs
Fluoxetinecapsule40 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinecapsule20 mg/1oralBarr Laboratories Inc.2001-08-02Not applicableUs
Fluoxetinecapsule40 mg/1oralTeva Pharmaceuticals USA Inc2002-01-30Not applicableUs
Fluoxetinecapsule40 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule10 mg/1oralState of Florida DOH Central Pharmacy2012-06-01Not applicableUs
Fluoxetinecapsule40 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule20 mg/1oralCardinal Health2013-02-04Not applicableUs
Fluoxetinecapsule10 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule40 mg/1oralRanbaxy Pharmaceuticals Inc.2005-07-20Not applicableUs
Fluoxetinecapsule10 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule40 mg/1oralRebel Distributors Corp2005-07-20Not applicableUs
Fluoxetinecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule40 mg/1oralPar Pharmaceutical Companies, Inc.2008-12-08Not applicableUs
Fluoxetinecapsule10 mg/1oralProficient Rx LP2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralCarlsbad Technology, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule10 mg/1oralContract Pharmacy Services Pa2010-07-30Not applicableUs
Fluoxetinecapsule20 mg/1oralTYA Pharmaceuticals2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
Fluoxetinecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-20Not applicableUs
Fluoxetinesolution20 mg/5mLoralTeva Pharmaceuticals USA Inc2001-08-02Not applicableUs
Fluoxetinecapsule10 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule20 mg/1oralRebel Distributors Corp2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralRebel Distributors Corp2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule10 mg/1oralCardinal Health2007-02-16Not applicableUs
Fluoxetinecapsule10 mg/1oralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Fluoxetine HClcapsule40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralPar Pharmaceutical, Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralPhysicians Total Care, Inc.2008-07-25Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralPhysicians Total Care, Inc.2008-10-23Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralKAISER FOUNDATION HOSPITALS2010-04-14Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2010-12-21Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs
Fluoxetine Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine Hydrochloridecapsule, delayed release pellets90 mg/1oralDr.Reddy's Laboratories Limited2010-03-24Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-03Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralSandoz Inc2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralAphena Pharma Solutions Tennessee, Inc.2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralNorthwind Pharmaceuticals2014-05-20Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralSandoz Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralContract Pharmacy Services Pa2010-04-05Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralSandoz Inc2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralPar Pharmaceutical, Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdofenBrainpharma
Animex-OnLaboratorios
FluoxerenMenarini
FontexLilly
LadoseLilly
Brand mixtures
NameLabellerIngredients
GaboxetinePhysician Therapeutics Llc
Olanzapine and FluoxetineTeva Pharmaceuticals USA Inc
Sentraflox Am-10Physician Therapeutics Llc
SentroxatinePhysician Therapeutics Llc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Fluoxetine Hydrochloride
Thumb
  • InChI Key: GIYXAJPCNFJEHY-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.110726557
  • Average Mass: 345.787
DBSALT000087
Categories
UNII01K63SUP8D
CAS number54910-89-3
WeightAverage: 309.3261
Monoisotopic: 309.134048818
Chemical FormulaC17H18F3NO
InChI KeyInChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
IUPAC Name
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
SMILES
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationLabeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.
PharmacodynamicsFluoxetine, an antidepressant agent belonging to the selective serotonin reuptake inhibitors (SSRIs), is used to treat depression, bulimia nervosa, premenstrual dysphoric disorder, panic disorder and post-traumatic stress. According to the amines hypothesis, a functional decrease in the activity of amines, such as serotonin and norepinephrine, would result in depression; a functional increase of the activity of these amines would result in mood elevation. Fluoxetine's effects are thought to be associated with the inhibition of 5HT receptor, which leads to an increase of serotonin level. Antagonism of muscarinic, histaminergic, and α1–adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.
Mechanism of actionMetabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionWell absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayed–release formulation, contain enteric–coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate–release formulations.
Volume of distribution
  • 20-45 L/kg
Protein binding94.5% bound to human serum proteins, including albumin and alpha-1-glycoprotein.
Metabolism

Limited data from animal studies suggest that fluoxetine may undergo first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and other metabolites. Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine. Norfluoxetine appears to be comparable pharmacologic potency as fluoxetine. Fluoxetine and norfluoxetine both undergo phase II glucuronidation reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-dealkylation to form p-trifluoromethylphenol, which is then subsequently metabolized to hippuric acid.

SubstrateEnzymesProduct
Fluoxetine
NorfluoxetineDetails
Fluoxetine
para-TrifluoromethylphenolDetails
Fluoxetine
Hippuric acidDetails
Fluoxetine
Fluoxetine glucuronideDetails
Norfluoxetine
Norfluoxetine glucuronideDetails
Norfluoxetine
Not Available
Norfluoxetine alcoholDetails
Norfluoxetine alcohol
Not Available
Norfluoxetine acidDetails
Route of eliminationThe primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. The S-enantiomer is eliminated more slowly and is the predominant enantiomer present at steady state.
Half life1-3 days [acute administration]; 4-6 days [chronic administration]; 4-16 days [norfluoxetine, acute and chronic administration].
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, restlessness, hypomania, and other signs of CNS excitation. LD50=284mg/kg (orally in mice). The most frequent side effects include: nervous system effects such as anxiety, nervousness, insomnia, drowsiness, fatigue or asthenia, tremor, and dizziness or lightheadedness; GI effects such as anorexia, nausea, and diarrhea; vasodilation; dry mouth; abnormal vision; decreased libido; abnormal ejaculation; rash; and sweating. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fluoxetine Action PathwayDrug actionSMP00426
Fluoxetine Metabolism PathwayDrug metabolismSMP00646
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.983
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5899
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.5459
Renal organic cation transporterInhibitor0.5633
CYP450 2C9 substrateNon-substrate0.7475
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7149
Ames testNon AMES toxic0.7105
CarcinogenicityNon-carcinogens0.8089
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.6048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6058
hERG inhibition (predictor II)Inhibitor0.8467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Eli lilly and co
  • Mutual pharmacal co
  • Watson laboratories inc
  • Alembic ltd
  • Alphapharm party ltd
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Carlsbad technology inc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Landela pharmaceutical
  • Mallinckrodt inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Lilly research laboratories div eli lilly and co
  • Actavis mid atlantic llc
  • Aurobindo pharma usa inc
  • Hi tech pharmacal co inc
  • Lannett holdings inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Warner chilcott inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral40 mg/1
Liquidoral20 mg/5mL
Solutionoral20 mg/5mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral60 mg/1
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsule, delayed release pelletsoral90 mg/1
Capsuleoral40 mg
Kit
Solutionoral20 mg
Capsuleoral20 mg
Capsuleoral10 mg
Liquidoral20 mg
Capsule, delayed releaseoral90 mg/1
Tabletoral10 mg/1
Tabletoral20 mg/1
Capsuleoral
Prices
Unit descriptionCostUnit
PROzac 20 mg/5ml Solution 120ml Bottle266.51USD bottle
PROzac Weekly 1 Package = 4 capsule (90 mg) Disp Pack140.77USD disp
Sarafem 7 10 mg tablet Box61.08USD box
Sarafem 7 20 mg tablet Each Box Contains 7 tablet59.55USD box
Prozac weekly 90 mg capsule34.5USD capsule
PROzac 40 mg capsule13.89USD capsule
Fluoxetine hcl powder8.32USD g
Sarafem 10 mg tablet7.91USD tablet
Sarafem 15 mg tablet7.91USD tablet
Sarafem 20 mg tablet7.91USD tablet
PROzac 20 mg capsule6.95USD capsule
PROzac 10 mg capsule6.77USD capsule
FLUoxetine HCl 40 mg capsule5.54USD capsule
PROzac 10 mg tablet4.31USD tablet
Fluoxetine hcl 20 mg tablet4.26USD tablet
Rapiflux 20 mg tablet3.11USD tablet
FLUoxetine HCl 20 mg capsule2.77USD capsule
Fluoxetine hcl 10 mg tablet2.72USD tablet
FLUoxetine HCl 10 mg capsule2.7USD capsule
Fxt 40 40 mg Capsule2.3USD capsule
Prozac 10 mg Capsule2.02USD capsule
Prozac 20 mg Capsule2.02USD capsule
Apo-Fluoxetine 10 mg Capsule1.13USD capsule
Co Fluoxetine 10 mg Capsule1.13USD capsule
Mylan-Fluoxetine 10 mg Capsule1.13USD capsule
Novo-Fluoxetine 10 mg Capsule1.13USD capsule
Nu-Fluoxetine 10 mg Capsule1.13USD capsule
Phl-Fluoxetine 10 mg Capsule1.13USD capsule
Pms-Fluoxetine 10 mg Capsule1.13USD capsule
Ratio-Fluoxetine Hydrochloride 10 mg Capsule1.13USD capsule
Sandoz Fluoxetine 10 mg Capsule1.13USD capsule
Apo-Fluoxetine 20 mg Capsule1.06USD capsule
Co Fluoxetine 20 mg Capsule1.06USD capsule
Mylan-Fluoxetine 20 mg Capsule1.06USD capsule
Novo-Fluoxetine 20 mg Capsule1.06USD capsule
Nu-Fluoxetine 20 mg Capsule1.06USD capsule
Phl-Fluoxetine 20 mg Capsule1.06USD capsule
Pms-Fluoxetine 20 mg Capsule1.06USD capsule
Ratio-Fluoxetine Hydrochloride 20 mg Capsule1.06USD capsule
Sandoz Fluoxetine 20 mg Capsule1.06USD capsule
FLUoxetine HCl 20 mg/5ml Solution1.03USD ml
Apo-Fluoxetine 4 mg/ml Liquid0.61USD liquid
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5910319 Yes1997-11-292017-11-29Us
US5945416 No1997-03-242017-03-24Us
US5985322 Yes1997-11-292017-11-29Us
US6960577 No1997-11-012017-11-01Us
USRE39030 No1997-05-292017-05-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point179-182 °CNot Available
water solubility50 mg/mL at 25 °CNot Available
logP4.05ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP4.09ALOGPS
logP4.17ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity80.37 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-0006-9200000000-dcf68dbfd090c7fdfe11View in MoNA
References
Synthesis Reference

Eduard Schwartz, Joseph Kaspi, Zinovi Itov, Gidon Pilarski, “Production of fluoxetine and new intermediates.” U.S. Patent US5225585, issued October, 1990.

US5225585
General References
  1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411-41. [PubMed:7623609 ]
  2. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB: A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471-9. [PubMed:4549929 ]
  3. Carlsson A, Wong DT: Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203. [PubMed:9315511 ]
  4. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998 Jun;32(6):692-8. [PubMed:9640489 ]
  5. Caley CF: Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997 Dec;31(12):1481-9. [PubMed:9416386 ]
External Links
ATC CodesN06AB03N06CA03
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (194 KB)
MSDSDownload (76.7 KB)
Interactions
Drug Interactions
Drug
AbciximabFluoxetine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.
AcenocoumarolFluoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Acetophenazine.
Acetylsalicylic acidFluoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
AlteplaseFluoxetine may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amoxapine.
AnistreplaseFluoxetine may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Apixaban.
AripiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluoxetine.
BenzquinamideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Benzquinamide.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Fluoxetine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluoxetine.
BuspironeBuspirone may increase the serotonergic activities of Fluoxetine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluoxetine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.
CarphenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Carphenazine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Fluoxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlormezanone.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Fluoxetine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluoxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorprothixene.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluoxetine.
CimetidineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.
CitalopramCitalopram may increase the QTc-prolonging activities of Fluoxetine.
Citric AcidFluoxetine may increase the anticoagulant activities of Citric Acid.
ClomipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clomipramine.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.
ClozapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clozapine.
CobicistatThe serum concentration of Fluoxetine can be increased when it is combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.
CollagenaseThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Collagenase.
CyproheptadineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateFluoxetine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.
DalteparinFluoxetine may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.
DarunavirThe serum concentration of Fluoxetine can be increased when it is combined with Darunavir.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Deoxycholic Acid.
DesipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.
DesmopressinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.
DextromethorphanFluoxetine may increase the serotonergic activities of Dextromethorphan.
DicoumarolFluoxetine may increase the anticoagulant activities of Dicoumarol.
DofetilideDofetilide may increase the QTc-prolonging activities of Fluoxetine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluoxetine.
DoxepinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.
DroperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Droperidol.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.
Edetic AcidFluoxetine may increase the anticoagulant activities of Edetic Acid.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fluoxetine.
EnoxaparinFluoxetine may increase the anticoagulant activities of Enoxaparin.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluoxetine.
Ethyl biscoumacetateFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
FencamfamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fencamfamine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Fluoxetine.
FloxuridineThe metabolism of Fluoxetine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Fluoxetine can be decreased when combined with Fluconazole.
FlupentixolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluspirilene.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Fluoxetine.
Fondaparinux sodiumFluoxetine may increase the anticoagulant activities of Fondaparinux sodium.
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Fluoxetine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Fluoxetine.
GlucosamineGlucosamine may increase the antiplatelet activities of Fluoxetine.
GoserelinGoserelin may increase the QTc-prolonging activities of Fluoxetine.
GranisetronGranisetron may increase the serotonergic activities of Fluoxetine.
HaloperidolFluoxetine may increase the QTc-prolonging activities of Haloperidol.
HeparinFluoxetine may increase the anticoagulant activities of Heparin.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluoxetine.
IcosapentFluoxetine may increase the antiplatelet activities of Icosapent.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.
ImipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Imipramine.
Insulin HumanFluoxetine may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluoxetine.
Ioflupane I 123Fluoxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IvabradineIvabradine may increase the QTc-prolonging activities of Fluoxetine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluoxetine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Fluoxetine.
LimaprostLimaprost may increase the antiplatelet activities of Fluoxetine.
LinezolidLinezolid may increase the serotonergic activities of Fluoxetine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.
LithiumLithium may increase the serotonergic activities of Fluoxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.
LoxapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Loxapine.
LumacaftorThe serum concentration of Fluoxetine can be decreased when it is combined with Lumacaftor.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Fluoxetine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mesoridazine.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluoxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Methotrimeprazine.
Methylene blueFluoxetine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluoxetine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Fluoxetine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Fluoxetine.
MolindoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Fluoxetine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Fluoxetine.
NifedipineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Obinutuzumab.
OctreotideOctreotide may increase the QTc-prolonging activities of Fluoxetine.
OlanzapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Olanzapine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Fluoxetine.
OndansetronThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Paliperidone.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Fluoxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Fluoxetine.
Peginterferon alfa-2bThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Fluoxetine.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Fluoxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Fluoxetine.
PhenindioneFluoxetine may increase the anticoagulant activities of Phenindione.
PhenprocoumonFluoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.
PimozideFluoxetine may increase the QTc-prolonging activities of Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Piperacetazine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Fluoxetine.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Fluoxetine.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Fluoxetine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Fluoxetine.
PropafenonePropafenone may increase the QTc-prolonging activities of Fluoxetine.
PropranololThe metabolism of Propranolol can be decreased when combined with Fluoxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Reserpine.
ReteplaseFluoxetine may increase the anticoagulant activities of Reteplase.
RidogrelFluoxetine may increase the anticoagulant activities of Ridogrel.
RisperidoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Risperidone.
RitonavirThe metabolism of Fluoxetine can be decreased when combined with Ritonavir.
RivaroxabanFluoxetine may increase the anticoagulant activities of Rivaroxaban.
SecobarbitalThe metabolism of Fluoxetine can be increased when combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sertindole.
StreptokinaseFluoxetine may increase the anticoagulant activities of Streptokinase.
SulfisoxazoleThe metabolism of Fluoxetine can be decreased when combined with Sulfisoxazole.
SulodexideFluoxetine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluoxetine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluoxetine.
TenecteplaseFluoxetine may increase the anticoagulant activities of Tenecteplase.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.
ThioridazineFluoxetine may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Thiothixene.
TiclopidineThe metabolism of Fluoxetine can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Fluoxetine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluoxetine.
TositumomabThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tositumomab.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Fluoxetine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluoxetine.
TrazodoneFluoxetine may increase the serotonergic activities of Trazodone.
TreprostinilFluoxetine may increase the anticoagulant activities of Treprostinil.
TrichlormethiazideFluoxetine may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.
UrokinaseFluoxetine may increase the anticoagulant activities of Urokinase.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Fluoxetine.
Vitamin EVitamin E may increase the antiplatelet activities of Fluoxetine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.
WarfarinFluoxetine may increase the anticoagulant activities of Warfarin.
ZiprasidoneFluoxetine may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation and nausea.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Richman A, Heinrichs SC: Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res. 2007 Apr;74(1):19-27. Epub 2007 Jan 9. [PubMed:17215106 ]
  2. Iceta R, Mesonero JE, Alcalde AI: Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007 Mar 27;80(16):1517-24. Epub 2007 Jan 20. [PubMed:17289086 ]
  3. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  4. Sanders AC, Hussain AJ, Hen R, Zhuang X: Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology. 2007 Nov;32(11):2321-9. Epub 2007 Mar 14. [PubMed:17356573 ]
  5. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B: Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res. 2007 Sep;32(9):1559-65. Epub 2007 May 8. [PubMed:17486443 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  4. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. FDA label
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. FDA label

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 25, 2016 03:19